We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+22.9%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.54B
AUM Growth
+$381M
(+33%)
Cap. Flow
+$151M
Cap. Flow
% of AUM
9.83%
Top 10 Holdings %
Top 10 Hldgs %
42.85%
Holding
66
New
16
Increased
21
Reduced
18
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$31.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$26.7M |
| 3 |
Regenxbio
RGNX
|
+$24.5M |
| 4 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
+$23.6M |
| 5 |
ICU Medical
ICUI
|
+$23.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$51.5M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$47.7M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$41M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$39.4M |
| 5 |
Centene
CNC
|
+$29.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.68% |
| 2 | Financials | 0.93% |
| 3 | Miscellaneous | 0.83% |
| 4 | Communication Services | 0.56% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Surgery Partners
SGRY
$1.79B
| $5.92M | 0.38% |
+303,500
| New | +$5.9M |
|
|
AVXS
52
DELISTED
AveXis, Inc. Common Stock
AVXS
| $3.45M | 0.22% |
+45,349
| New | +$2.81M |
|
53
Aclaris Therapeutics
ACRS
$885M
| $2.71M | 0.18% |
90,700
-3,500
| -4% | -$101K |
|
|
RARX
54
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $2.36M | 0.15% |
110,769
-69,541
| -39% | -$1.33M |
|
55
Aurinia Pharmaceuticals
AUPH
$2.17B
| $1.03M | 0.07% |
140,243
+103,500
| +282% | +$478K |
|
56
UnitedHealth
UNH
$353B
| $298K | 0.02% |
1,820
| – | – |
|
|
AMED
57
DELISTED
Amedisys
AMED
| $247K | 0.02% |
+4,826
| New | +$230K |
|
|
ADVM
58
DELISTED
Adverum Biotechnologies
ADVM
| $60K | ﹤0.01% |
2,224
| – | – |
|
|
CSLT
59
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $37K | ﹤0.01% |
10,229
| – | – |
|
|
60
Centene
CNC
$32B
| – | – |
-1,033,196
| Closed | -$29.2M |
|
61
iShares Biotechnology ETF
IBB
$10.5B
| – | – |
-13,500
| Closed | -$1.19M |
|
62
iRhythm Holdings
IRTC
$3.96B
| – | – |
-228,800
| Closed | -$6.86M |
|
|
NVRO
63
DELISTED
NEVRO CORP.
NVRO
| – | – |
-260,380
| Closed | -$18.9M |
|
|
ARIA
64
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| – | – |
-3,838,376
| Closed | -$47.7M |
|
|
WOOF
65
DELISTED
VCA Inc.
WOOF
| – | – |
-70,040
| Closed | -$4.81M |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q1 2017 Portfolio in Review
As of Q1 2017, Redmile Group held 66 positions worth $1.54B, up 33% from $1.16B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Redmile Group deployed $151M of net new capital in Q1 2017, opening 16 new positions and adding to 21 existing holdings. Its largest new stake was Syneos Health, Inc. Class A Common Stock: 633,779 shares worth $29.1M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Miscellaneous.
On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $51.5M trimmed.
- Redmile Group's largest Q1 2017 buy was Syneos Health, Inc. Class A Common Stock: 633,779 shares worth $29.1M.
- Redmile Group added most to Alder Biopharmaceuticals in Q1 2017, an estimated $21.9M increase.
- Redmile Group's biggest Q1 2017 reduction was Seagen Inc. Common Stock, cutting an estimated $51.5M.
- Redmile Group fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $47.7M.
- Redmile Group's ten largest holdings make up 43% of its $1.54B portfolio in Q1 2017.
- Redmile Group opened 16 new positions and closed 6 in Q1 2017.
- Redmile Group's portfolio value rose 33% quarter-over-quarter to $1.54B.
Based on Redmile Group's 13F filing for Q1 2017, filed 15 May 2017.